Mode
Text Size
Log in / Sign up
Phase 4 N=32 Randomized Treatment

Intravenous Lidocaine Versus Morphine for Severe Pain in the ED

Pain

Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Apr 2020
Primary outcome: Primary: Pain Score (NRS 0-10) — 5.1; 4.2 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Intravenous lidocaine (Drug); Intravenous morphine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Alameda Health System
Primary completion
Sep 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Score (NRS 0-10)
5.6; 4.6
SECONDARY
Pain Score (NRS 0-10)
5.6; 4.6
SECONDARY
Pain Score (NRS 0-10)
5.6; 4.6
SECONDARY
Pain Score (NRS 0-10)
5.6; 4.6
SECONDARY
Pain Score (NRS 0-10)
5.6; 4.6
SECONDARY
Pain Score (NRS 0-10)
5.6; 4.6
SECONDARY
Pain Relief at 10 Minutes Compared to Baseline.
1.1; 2.0
SECONDARY
Pain Relief at 20 Minutes Compared to Baseline.
1.8; 2.8
SECONDARY
Pain Relief at 30 Minutes Compared to Baseline.
2.2; 3.4
SECONDARY
Pain Relief at 40 Minutes Compared to Baseline.
2.9; 4.2
SECONDARY
Pain Relief at 50 Minutes Compared to Baseline.
3.6; 4.4
SECONDARY
Pain Relief at 60 Minutes Compared to Baseline.
4.1; 4.8
SECONDARY
Number of Participants Requiring Rescue Medications
5; 4
SECONDARY
Patient Satisfaction
13; 14
SECONDARY
Number of Participants Reporting Adverse Events
2; 6

Summary

Objective: Evaluate the analgesic efficacy of intravenous (IV) lidocaine versus provider chosen dose of IV morphine for the treatment of severe pain in the emergency department. Study design: Open-label, randomized controlled pilot study.

Eligibility Criteria

Inclusion Criteria

  • Subject has severe pain (NRS ≥7)
  • Subject has anticipated ED stay of ≥1 hour

Exclusion Criteria

  • High acuity trauma patients
  • Patients deemed to critically ill by ED provider
  • Active psychosis
  • Pregnancy
  • History of heart block or bradycardia
  • Allergy to lidocaine or amide type local anesthetic
  • History of seizures
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02912195). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search